Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Proteros and Priaxon Announce Lead Discovery Collaboration on Protein-Protein Interaction Targets

Published: Tuesday, April 09, 2013
Last Updated: Tuesday, April 09, 2013
Bookmark and Share
Proteros biostructures GmbH announced they entered into a Lead Discovery Collaboration with Priaxon AG to jointly develop lead compounds for high value protein-protein interaction (PPI) drug targets.

The combination of Proteros’ structure guided discovery with Priaxon’s PPI-directed drug discovery platforms will be focused on the identification of novel small molecule modulators for PPI targets. As part of this collaboration, Proteros will apply its integrated Lead Discovery expertise and technologies in the field of structural biology, biophysics and screening. Priaxon will apply its proprietary drug discovery platform  Priaxplore®, which combines a proprietary PPI focused chemical space with special tailor made chemoinformatic methods for the identification of potential PPI modulators.

“The combination of Proteros’ strength in structural biology and biophysics with the Priaxon’s PPI focused drug discovery platform Priaxplore® forms an excellent basis to make PPI targets of high interest addressable by small molecule modulators" said Dr. Juergen Kolb, CEO of Priaxon.

Dr. Torsten Neuefeind, CEO of Proteros, stated: "We are very pleased to have formed this relationship with Priaxon. Both companies have complementary platforms as well as an established track-record. PPIs are a big challenge in drug discovery and the use of structural information, computational chemistry and Priaxons’ validated chemistry approach allows us to respond to the industry demand for such targets in a unique manner”.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Proteros Appoints Dr. Torsten Hoffmann as Chief Scientific Officer
Dr. Hoffmann will support the further growth of the Company’s Discovery business.
Tuesday, June 30, 2015
Proteros Achieves Key Milestone in Janssen Lead Discovery Collaboration
Company to discover potent and selective small molecule inhibitor series against a novel protein target.
Tuesday, May 19, 2015
Proteros Enters into a Collaboration with Bayer
Collaboration to develop new cardiovascular drug compounds for an integral membrane protein.
Saturday, January 10, 2015
Proteros Announces Changes in Management Team
The changes see a new Chief Financial Officer, and a promotion to Chief Operating Officer.
Monday, May 12, 2014
Proteros Elects New Supervisory Board Member
Shareholders confirmed the appointment of Prof. Eric-Paul Pâques as a new member of the Supervisory Board.
Thursday, February 20, 2014
Rodin Therapeutics Applies Insights of Epigenetics to Neurological Disorders
Founded by Atlas Venture and Proteros biostructures.
Monday, July 01, 2013
Proteros and Eisai Achieve Target in Lead Discovery Project
Companies delivering kinetically optimized lead compounds.
Tuesday, May 07, 2013
UCB and Proteros Expand Collaboration
Expansion of the ongoing structural biology collaboration will include additional therapeutic areas.
Monday, September 17, 2012
Proteros Announces Successful Close of Financing Round
Largest-ever financing allows for expansion of drug discovery capabilities.
Tuesday, August 07, 2012
Proteros Appoints Dr Klaus Hinterding
Dr Klaus Hinterding, formerly at Hoffmann-La Roche Ltd, joins Proteros biostructures GmbH as Chief Scientific Officer and member of the management board.
Monday, February 13, 2012
Proteros Obtains CIR Accreditation
Accreditation allows eligible clients to receive 30% of their R&D costs in tax credits.
Wednesday, January 25, 2012
Rigel and Proteros Renew X-ray Protein Crystallography Collaboration
Proteros will provide X-ray structure analysis of protein-compound complexes for specific targets to support Rigel’s discovery efforts.
Thursday, August 04, 2011
AMRI and Proteros Biostructures GmbH Announce Strategic Alliance
AMRI and Proteros Biostructures GmbH announces that they have signed an agreement for a joint offering to the life sciences industry.
Wednesday, July 20, 2011
Rigel and Proteros Renew X-ray Protein Crystallography Collaboration
Proteros will provide X-ray structure analysis of protein-compound complexes for specific targets to support Rigel’s discovery efforts.
Thursday, July 14, 2011
Proteros and Institut Pasteur Korea Establish Discovery Services Collaboration in the Field of Infectious Diseases
Proteros will apply its know-how, experience of structural analysis and proprietary X-ray crystallography platform to support IP-K’s mission to develop therapeutics for infectious diseases.
Wednesday, May 25, 2011
Scientific News
A New Way to Look at MOFs
International study challenges prevailing view on how metal organic frameworks store gases.
Major Advance in Crystal Structure Prediction Methods
The Cambridge Crystallographic Data Centre (CCDC) announces that the results of its 6th blind test of crystal structure prediction methods demonstrate significant advancement in in comparison with previous tests.
Protein Structure Discovery Opens Window on Basic Life Process
Biochemists at Oregon State University have made a fundamental discovery about protein structure that sheds new light on how proteins fold, which is one of the most basic processes of life.
Clearest Ever Images of Enzyme that Plays Key Roles in Aging, Cancer
UCLA-led research on telomerase could lead to new strategies for treating disease
New Approach to Treating Heparin-induced Blood Disorder
A potential treatment for a serious clotting condition that can strike patients who receive heparin to treat or prevent blood clots may lie within reach by elucidating the structure of the protein complex at its root.
Escape Prevention
Studying flu virus structure brings us a step closer to a permanent vaccine.
Structure of Protein at Root of Muscular Disease Decoded
Researchers at Rice University and Baylor College of Medicine have unlocked the structural details of a protein seen as key to treating a neuromuscular disease.
A Natural Light Switch
MIT scientists identify and map the protein behind a light-sensing mechanism.
First Complete Structural Study Of A Pegylated Protein
Significant data obtained at NUI Galway reports first crystal structure of a protein modified with a single PEG chain.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos